Hemophilia & Factor Replacement TRACKER Launched
The Guidepoint Hemophilia & Factor Replacement TRACKER reports monthly treatment data for the US hemophilia A, hemophilia B and von Willebrand disease markets in near real-time. Timely quantitative and qualitative data, deep dives and drill downs uncover emerging trends and a unique perspective unavailable anywhere else.
Contact Us to schedule a demo.
Supplementary Data – Have you seen it?
The Guidepoint TRACKER analyst team often collects data through directed questions addressing emerging market dynamics. This data can be found in the Supplementary section.
Recent examples: US Transcatheter TRACKER patient risk stratification since Aug 2016 and in Sept 2016 following Pharming’s Rhucin/Ruconest rights reacquisition announcement, a series of HAE TRACKER questions focused on awareness, perception, future use and more.
The US CRC Screening TRACKER panel expansion is complete. New sites with data since Jan 2017 increase test volume capture by >150%. Other recent expansions include Dermal Fillers and Neurotoxins (Aug 2016), US PAH (Jun 2015) US CRM (May 2015) and Cochlear Implants (Jan 2015).
Let us know which therapeutic, device, or non-healthcare markets you’d like to see covered:
Feedback & Suggestions